Zeposia
| Chemical Name | ozanimod |
| Dosage Form | Capsules (oral; 0.23 mg, 0.46 mg, 0.92 mg) |
| Drug Class | Modulators |
| System | Nervous |
| Company | Celgene Corporation |
| Approval Year | 2020 |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.